Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma

Background: Chemotherapy with Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD regimen) cannot cure all patients with Hodgkin lymphoma. In this study, we evaluated the efficacy and adverse effect of a new regimen consist Irinotecan, Cisplatin, and Dexamethasone (ICD) in relapsed and refract...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabarraee, Mahdi, Rezaee, Atefeh, Abolghasemi, Sara, Ghadiany, Mojtaba, Tavakoli Ardakani, Maria, Mahdizadeh, Mahshid, Hamidi, Neda, Ghasemi, Katayoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560643/
https://www.ncbi.nlm.nih.gov/pubmed/37817972
http://dx.doi.org/10.18502/ijhoscr.v17i3.13309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560643/
https://www.ncbi.nlm.nih.gov/pubmed/37817972
http://dx.doi.org/10.18502/ijhoscr.v17i3.13309

Ejemplares similares